keyword
MENU ▼
Read by QxMD icon Read
search

Mantle cell

keyword
https://www.readbyqxmd.com/read/29034364/microenvironmental-agonists-generate-de-novo-phenotypic-resistance-to-combined-ibrutinib-plus-venetoclax-in-cll-and-mcl
#1
Kallesh D Jayappa, Craig A Portell, Vicki L Gordon, Brian J Capaldo, Stefan Bekiranov, Mark J Axelrod, L Kyle Brett, Julia D Wulfkuhle, Rosa I Gallagher, Emanuel F Petricoin, Timothy P Bender, Michael E Williams, Michael J Weber
De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously performed a combinatorial drug screen and identified the Bcl-2 inhibitor venetoclax (VEN) as a promising partner for combination with IBR in Mantle Cell Lymphoma (MCL). We have opened a multi-institutional clinical trial to test this combination...
June 13, 2017: Blood Advances
https://www.readbyqxmd.com/read/29032352/physiological-impacts-of-acute-cu-exposure-on-deep-sea-vent-mussel-bathymodiolus-azoricus-under-a-deep-sea-mining-activity-scenario
#2
Inês Martins, Joana Goulart, Eva Martins, Rosa Morales-Román, Sergio Marín, Virginie Riou, Ana Colaço, Raul Bettencourt
Over the past years, several studies have been dedicated to understanding the physiological ability of the vent mussel Bathymodiolus azoricus to overcome the high metal concentrations present in their surrounding hydrothermal environment. Potential deep-sea mining activities at Azores Triple junction hydrothermal vent deposits would inevitably lead to the emergence of new fluid sources close to mussel beds, with consequent emission of high metal concentrations and potential resolubilization of Cu from minerals formed during the active phase of the vent field...
October 9, 2017: Aquatic Toxicology
https://www.readbyqxmd.com/read/29024198/mucocele-like-lesions-diagnosed-on-breast-core-biopsy-low-risk-of-upgrade-and-subsequent-carcinoma
#3
Gloria Zhang, Dana Ataya, Paulette L Lebda, Benjamin C Calhoun
Mucocele-like lesions of the breast diagnosed on core biopsy are usually excised to exclude the possibility of partial sampling of an invasive mucinous carcinoma. The goal of this study was to correlate the pathologic and radiologic features of mucocele-like lesions to determine if excision is mandatory. Over a 16 year period we identified 32 patients with mucocele-like lesions diagnosed on 27 (84%) stereotactic and 5 (16%) ultrasound-guided core biopsies. The indications for core biopsy were: calcifications in 24 (75%), a mass in 7 (22%), and a mass with calcifications in 1 (3%)...
October 11, 2017: Breast Journal
https://www.readbyqxmd.com/read/29022078/survival-benefit-of-mantle-cell-lymphoma-patients-enrolled-in-clinical-trials-a-joint-study-from-the-lysa-group-and-french-cancer-registries
#4
Alix Augustin, Steven Le Gouill, Rémy Gressin, Aurélie Bertaut, Alain Monnereau, Anne-Sophie Woronoff, Brigitte Trétarre, Patricia Delafosse, Xavier Troussard, Anne Moreau, Olivier Hermine, Marc Maynadié
PURPOSE: Mantle cell lymphoma (MCL) is a rare non-Hodgkin's lymphoma entity with a poor prognosis. Therapeutic advances have improved the survival of patients enrolled in clinical trials; however, their impact on patients outside clinical trials remains unclear. In this work, we compared patient outcome inside and outside clinical trials. METHODS: We identified MCL patients recorded in six French population-based registries between 2008 and 2012 to perform a comparison with patients enrolled in two prospective multicenter MCL clinical trials conducted by the LYSA group during the same period...
October 11, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29021211/pfmg1-promotes-osteoblast-differentiation-and-prevents-osteoporotic-bone-loss
#5
Liyuan Li, Pan Wang, Kaiqiang Hu, Xiaoyan Wang, Wenping Cai, Chao Ai, Shangfeng Liu, Zhao Wang
Nacre is a widely used mineral medicine that has been reported to have beneficial effects in bone remodeling without an increase in inflammation. Water-soluble nacre matrix has been demonstrated to be responsible for the effect, yet core active ingredients are unknown. Pinctada fucata mantle gene 1 (PFMG1) was first discovered in the mantle tissue of Pinctada fucata. The protein has 2 EF-hands, a calcium-binding domain. PFMG1 protein can affect the growth of calcium carbonate crystals in vitro Here, we demonstrate that PFMG1 affects cell-cycle distribution and promotes preosteoblast proliferation...
October 11, 2017: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/29019439/ibrutinib-as-salvage-therapy-in-mantle-cell-lymphoma-with-central-nervous-system-involvement-in-a-pretreated-unfit-patient
#6
Orsola Vitagliano, Fabio Trastulli, Fabiana Cacace, Stefania Leone, Mara Memoli, Giulia Scalia, Marianna Notarangelo, Ciro G Mainolfi, Amalia De Renzo, Fabrizio Pane
No abstract text is available yet for this article.
October 11, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29019324/clinico-hematological-profile-of-184-patients-with-non-hodgkin-s-lymphoma-an-experience-from-southern-pakistan
#7
Sadia Sultan, Syed Mohammed Irfan, Anila Rashid, Saira Parveen, Neesha Nawaz
BACKGROUND: Non-Hodgkin lymphoma (NHL) is a diverse group of lymphoma comprises of divergent tumors with paradoxical clinical behaviors and potential difference in response to therapy. We conducted a data-base analysis on NHL patients to evaluate the clinico-epidemiological features and WHO spectrum of NHL in Pakistani patients. MATERIALS AND METHODS: This descriptive study was conducted over a period of 5 years from January 2011 to December 2015 at Hematology department of Liaquat National Hospital...
September 2017: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/29016193/the-possible-emergence-of-life-and-differentiation-of-a-shallow-biosphere-on-irradiated-icy-worlds-the-example-of-europa
#8
Michael J Russell, Alison E Murray, Kevin P Hand
Irradiated ice-covered ocean worlds with rocky mafic mantles may provide the conditions needed to drive the emergence and maintenance of life. Alkaline hydrothermal springs-relieving the geophysical, thermal, and chemical disequilibria between oceans and tidally stressed crusts-could generate inorganic barriers to the otherwise uncontrolled and kinetically disfavored oxidation of hydrothermal hydrogen and methane. Ionic gradients imposed across these inorganic barriers, comprising iron oxyhydroxides and sulfides, could drive the hydrogenation of carbon dioxide and the oxidation of methane through thermodynamically favorable metabolic pathways leading to early life-forms...
October 10, 2017: Astrobiology
https://www.readbyqxmd.com/read/28988912/maintenance-rituximab-in-mantle-cell-lymphoma
#9
Talha Khan Burki
No abstract text is available yet for this article.
October 5, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28984300/cd200-expression-in-mantle-cell-lymphoma-identifies-a-unique-subgroup-of-patients-with-frequent-ighv-mutations-absence-of-sox11-expression-and-an-indolent-clinical-course
#10
Zhihong Hu, Yi Sun, Ellen J Schlette, Guilin Tang, Shaoying Li, Jie Xu, C Cameron Yin, Ken H Young, Keyur Pravinchandra Patel, Roberto N Miranda, Maitrayee Goswami, Michael Wang, Jeffrey L Jorgensen, L Jeffrey Medeiros, Sa A Wang
CD200, a marker currently utilized in the diagnosis of B-cell lymphoma, is uniformly positive in chronic lymphocytic leukemia/chronic lymphocytic leukemia, and is usually absent in mantle cell lymphoma. Over a 6 year-period, of 668 mantle cell lymphoma assessed by flow cytometry, CD200 expression was detected in 25 patients (~4%). All 25 patients had bone marrow involvement; however, 11 (44%) patients had no nodal or extranodal disease and belonged to non-nodal leukemic variant mantle cell lymphoma. Morphologically, bone marrow showed an unusual interstitial infiltrative pattern in 14/25 (56%) and small round cells resembling chronic lymphocytic leukemia in 9/25 (36%)...
October 6, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28983798/rituximab-in-b-cell-hematologic-malignancies-a-review-of-20-years-of-clinical-experience
#11
REVIEW
Gilles Salles, Martin Barrett, Robin Foà, Joerg Maurer, Susan O'Brien, Nancy Valente, Michael Wenger, David G Maloney
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its first approval 20 years ago, intravenously administered rituximab has revolutionized the treatment of B-cell malignancies and has become a standard component of care for follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma...
October 5, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28979842/msp22-8-is-a-protease-inhibitor-like-protein-involved-in-shell-mineralization-in-the-edible-mussel-mytilus-galloprovincialis
#12
Juan Calvo-Iglesias, Daniel Pérez-Estévez, África González-Fernández
The mussel shell protein 22.8 (MSP22.8) is recognized by a monoclonal antibody (M22.8) directed against larvae of the mussel Mytilus galloprovincialis. After being secreted by cells of the mantle-edge epithelium into the extrapallial (EP) space (the gap between the mantle and the shell), the protein is detected in the extrapallial fluid (EPF) and EP hemocytes and finally becomes part of the shell matrix framework in adult specimens of M. galloprovincialis. In the work described here, we show how MSP22.8 is detected in EPF samples from different species of mussels (M...
October 2017: FEBS Open Bio
https://www.readbyqxmd.com/read/28978845/treatment-for-mantle-cell-lymphoma
#13
Koji Izutsu
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma characterized by CD5+, CCND1+, and the CCND1-IGH translocation. Although patients with MCL respond, at least temporarily, to conventional chemotherapy, they eventually have a relapse and the prognosis is generally poor. As a primary treatment option for patients with untreated MCL, a rituximab-containing chemotherapy regimen is administered according to the patient's eligibility for high-dose chemotherapy followed by autologous stem cell transplantation (ASCT)...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28974340/a-possible-new-morphological-variant-of-mantle-cell-lymphoma-with-plasma-cell-type-castleman-disease-like-features
#14
Takuro Igawa, Rika Omote, Hiaki Sato, Kohei Taniguchi, Katsuya Miyatani, Tadashi Yoshino, Yasuharu Sato
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma characterized by overexpression of cyclin D1 resulting from t(11;14)(q13;q32) translocation. Herein, we report 3 cases of MCL with features of plasma cell-type Castleman disease (CD). The 3 patients were all men, ranging from 51 to 74 years in age, and they all presented with systemic lymphadenopathy with anemia, hypoalbuminemia, elevated serum levels of C-reactive protein, and polyclonal hypergammaglobulinemia. Lymph node biopsy specimens of the 3 cases showed histological features of plasma cell-type CD, including atrophic germinal centers and interfollicular plasmacytosis, with no light chain restriction...
September 18, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28973700/hematologic-malignancies-discovered-on-investigation-of-breast-abnormalities
#15
Alaa Alsadi, Dianna Lin, Hussein Alnajar, Arlen Brickman, Colin Martyn, Paolo Gattuso
OBJECTIVES: Hematological malignancies of the breast share a presentation similar to primary breast carcinomas but differ substantially in therapeutic approach and clinical outcomes. In this study, we investigate the frequency of hematological malignancies, their relative primary and secondary occurrences, and further characterize the distinct histopathologies of these malignancies with a special focus on lymphomas. To our knowledge this is one of the largest and most comprehensive studies of breast hematologic malignancies...
October 2017: Southern Medical Journal
https://www.readbyqxmd.com/read/28971900/pan-phosphatidylinositol-3-kinase-inhibition-with-buparlisib-in-patients-with-relapsed-and-refractory-non-hodgkin-lymphoma
#16
Anas Younes, Gilles Salles, Giovanni Martinelli, Robert Gregory Bociek, Dolores Caballero Barrigon, Eva González Barca, Mehmet Turgut, John Gerecitano, Oliver Kong, Chaitali Babanrao Pisal, Ranjana Tavorath, Won Seog Kim
Phosphatidylinositol 3-kinase mechanistic target of rapamycin pathway activation plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label Phase II study evaluated buparlisib (BKM120), a pan-class I Phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or refractory non-Hodgkin lymphoma. Patients received buparlisib 100 mg once daily in three separate cohorts (diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular lymphoma) until progression, intolerance, or withdrawal of consent...
September 29, 2017: Haematologica
https://www.readbyqxmd.com/read/28967896/post-autologous-transplant-maintenance-therapies-in-lymphoma-current-state-and-future-directions
#17
REVIEW
P A Riedell, M R Bishop
Disease relapse following high-dose chemotherapy and autologous stem cell transplant (ASCT) remains the principal cause of mortality in patients with relapsed or refractory lymphomas. In an effort to prevent post-ASCT relapse, a number of studies have evaluated the role of maintenance therapy with varying success. In diffuse large B-cell lymphoma, studies evaluating maintenance rituximab (MR) following ASCT failed to demonstrate improved outcomes. In follicular lymphoma, MR was associated with an improvement in PFS; however, no overall survival (OS) benefit was noted...
October 2, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28961827/observation-as-the-initial-management-strategy-in-patients-with-mantle-cell-lymphoma
#18
P Abrisqueta, D W Scott, G W Slack, C Steidl, A Mottok, R D Gascoyne, J M Connors, L H Sehn, K J Savage, A S Gerrie, D Villa
Background: Patients with mantle cell lymphoma (MCL) follow a heterogeneous clinical course. While they generally require treatment initiation shortly after diagnosis, it is unclear whether deferring treatment in selected patients with an indolent clinical behavior affects their overall outcome. Patients and methods: In this population-based study, all patients diagnosed with MCL during 1998-2014 were identified in the British Columbia Cancer Agency Lymphoid Cancer Database...
October 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28960405/expression-of-connexin43-cx43-in-the-human-hair-follicle-emphasis-on-the-cx43-protein-levels-in-the-bulge-and-through-the-keratinization-process
#19
A Fernandez-Flores, A Varela-Vazquez, M D Mayan, E Fonseca
INTRODUCTION: Gap junctions form communication compartments between cells. These channels assemble from connexin (Cx) subunits. OBJECTIVE: To investigate the immunoexpression of Cx43 in adult human hair follicles. MATERIALS AND METHODS: Cases were retrospectively obtained from our archives. RESULTS: We identified immunoexpression of Cx43 in the matrix, the papilla, the outer root sheath, the bulge, the medulla, the cortex, the shaft, and the secretory part of the sebaceous gland...
September 28, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28959500/phase-1-study-of-inotuzumab-ozogamicin-combined-with-r-gdp-for-the-treatment-of-patients-with-relapsed-refractory-cd22-b-cell-non-hodgkin-lymphoma
#20
Randeep Sangha, Andrew Davies, Nam H Dang, Michinori Ogura, David A MacDonald, Revathi Ananthakrishnan, M Luisa Paccagnella, Erik Vandendries, Joseph Boni, Yeow Tee Goh
Objective: To evaluate safety, tolerability, and preliminary activity of inotuzumab ozogamicin (InO) plus rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) in patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma (NHL). Methods: Patients received InO plus R-GDP (21-day cycle; six-cycle maximum) using up-and-down dose-escalation schema for gemcitabine and cisplatin to define the highest dosage regimen(s) with acceptable toxicity (Part 1; n = 27). Part 2 (n = 10) confirmed safety and tolerability; Part 3 (n = 18) evaluated preliminary efficacy...
2017: Journal of drug assessment
keyword
keyword
52380
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"